EUROPEAN COMMISSION
JOINT RESEARCH CENTRE

Directorate F – Health and Food
Disease Prevention

Annual Declaration of Interests[1] (DoI) form
(v2, 01 July 2026)

European Commission initiative on Lung Cancer (EC-LuC)

Please answer each of the questions below.
If the answer to any of the questions is "Yes"[2], please complete the corresponding fields, describing the circumstances, as appropriate.

If you do not submit a filled-in and signed DoI form, please consider that you cannot be involved in the EC-LuC activities.
If you do not disclose relevant activities of interest for the EC-LuC, your role may be revised.

[1] According to EC's Decision C(2016) 3301 establishing horizontal rules on the creation and operation of Commission expert groups, Articles 2(4) and 10, each member of an expert group has to complete a DoI form
https://ec.europa.eu/transparency/documents-register/detail?ref=C(2016)3301&lang=en

[2] Answering "Yes" to the questions on this form does not automatically limit your participation in the EC-LuC activities. Your answers will be reviewed to determine whether you have a conflict of interest (CoI) (*i.e.* any interest that may affect, or may reasonably be perceived to affect, an expert's objectivity and independence).

Name and Surname:	**Martina Vrankar**

Activities (2021 - 2025)	**Yes/No**	**Period (From - To)**	**Information**	**Details**
1. Do you have current investments[3] in a legal entity[4] with an interest related to lung cancer which either: • **has a value of more than 10.000 EUR, or** • **entitles you to a voting right of 5% or more?**	Yes ☐ No ☒	MM/YYYY – MM/YYYY	If 'yes', please specify: • Name of entity; • Place; • Type of entity: public, private.	[Please describe your role.]

[3] **Investments** refer to stocks, bonds, stock options, other securities as well as to commercial business interests (*e.g.*, proprietorships, partnerships, joint ventures, board memberships, controlling interest in a company).

[4] **Legal entity** refers to any commercial business, industry association, consultancy, research institution or other enterprise whose funding is significantly derived from commercial sources. It also includes independent own commercial businesses, law offices, consultancies or similar.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
2. Within the past 5 years, were you employed (remunerated or non-remunerated post) or have you had any other professional relationship with a legal entity or any other body, with an interest related to lung cancer? **A. Employment**	Yes ☒ No ☐	1997 – current	Institute of Oncology, Ljubljana, Slovenia; • Public hospital • Salary for employment	Employed as a Radiation Oncologist at the Division of Radiotherapy, Institute of Oncology Ljubljana.
B. Consultancy, including advisory activities	Yes ☒ No ☐	12/2024 10/2024 10/2023 10/2022 04/2022 12/2021	AstraZeneca, Slovenia, private 1020 € AstraZeneca, Slovenia, private 1105 € AstraZeneca, Slovenia, private 1200 € Takeda, Slovenia, private, 900 € MSD, Slovenia, private, 1000 € Amgen, Slovenia, private, 1110 €	Advisory Board Advisory Board Advisory Board Advisory Board Advisory Board Advisory Board
C. Non-remunerated post	Yes ☐ No ☒	MM/YYYY – MM/YYYY	If 'ye's, please specify: • Name of the entity; • Place; • Type of the entity: public, private;	[Please describe your role.]

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
D. Legal representation[5]	Yes ☒ No ☐	2021 – ongoing	• Head of the NCCP Expert Group for Lung Cancer • Member of the NCCP Expert Council	Coordinating national activities and developing recommendations for lung cancer prevention, early detection, diagnosis, treatment, and screening. Contributing to the development of national cancer control policies and strategic decision-making.

[5] **Legal representation** refers to the representation of natural or legal persons through other persons in accordance with national law. For example, the president of a company is the legal representative of that company.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
3. Regarding research related to lung cancer within the past 5 years: **A. Have you been an investigator in research studies on lung cancer?**	Yes ☒ No ☐	2022–2026 2023 - ongoing	• Principal Investigator of the ASTRES study in Slovenia. • Sponsored by the Roche • Study fees to the Institution of Oncology Ljubljana • Framework development for evidence-based, sustainable implementation of organised population-based lung cancer screening in Slovenia (LUKA) • Financially supported by the Ministry of Health and the Public Agency for Research. • Study fees to the Institution of Oncology Ljubljana	A phase II, single-arm study of atezolizumab in patients with locally advanced, unresectable stage III non-small cell lung cancer who have not progressed after platinum-based concurrent chemoradiation Leading the research project.
B. If yes, for the aforementioned research studies, did you receive support[6]?	Yes ☒ No ☐	2023-ongoing	• Financially supported by the Ministry of Health and the Public Agency for Research. • Study fees to the institution • 38.500 Eur (Total funding allocated to the home institution)	Framework development for evidence-based, sustainable implementation of organised population-based lung cancer screening in Slovenia (LUKA)

[6] **Support** refers to research support (i.e. grants, collaborations, sponsorships) as well as to non-monetary support (equipment, facilities) and other type of support (i.e. honoraria for being a speaker, holding a training).

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
4. Do you have membership in national or international organisations[7], including committees, working groups, collaborative platforms, managing bodies or scientific advisory bodies or any decision making bodies with an interest in lung cancer?	Yes ☒ No ☐	2022 – 2026 2024 - ongoing	Member of the ASTRES Study Steering Committee Member of the EUCanScreen project	Advisory body providing expert input, without decision-making authority. Involved in preparing the scientific basis for the development of guidelines for implementing the new lung cancer screening programme.
5. Do you have intellectual property rights (IPR)[8] related to lung cancer?	Yes ☐ No ☒	MM/YYYY – MM/YYYY	Please specify the title of the IPR.	[Please describe the IPR.]
6. Within the past 5 years: **A. Have you provided any expert opinion or testimony in the field of lung cancer, for a legal entity or other body as part of a regulatory, legislative or judicial process?**	Yes ☐ No ☒	MM/YYYY – MM/YYYY	Please mention the activity.	[Please describe the activity.]

[7] **Organisation** refers to a governmental, international or non-profit organisation.

[8] **Intellectual property rights** refer to patents, trademarks, or copyrights (including pending applications) as well as proprietary know-how in a substance, technology or process.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
B. Have you held an office or other position, paid or unpaid, where you represented interests or defended an opinion in the field of lung cancer?	Yes ☐ No ☒	MM/YYYY – MM/YYYY	Please mention the activity.	[Please describe the activity.]
7. Do any of your immediate family members[9] have direct interests related to lung cancer that could undermine your independence?	Yes ☐ No ☒	MM/YYYY – MM/YYYY	Please mention the interest.	[Please describe the interest.]
8. Within the past 5 years, did you take part in other activities with interests related to lung cancer?	Yes ☒ No ☐	2019 - ongoing	Coordinator and Editor of the Slovenian Guidelines for the Management of Patients with Lung Cancer, 2019, 2022	Coordinator and Editor

[9] **Immediate family members** refer to family members and relatives (spouse, parents, children, brothers and sisters, irrespective of whether they live at the same address or not) or other persons under the care of the members of the household of the expert.

Notes:

If you declared any direct interests of your immediate family members, it is your responsibility to inform them about how data on their interests are collected and published[10] before you send the DoI form to the Joint Research Centre (JRC), EC.

After submission of this form, you need to inform the JRC in case of any new activity during the course of the year by sending an e-mail as soon as possible at: JRC-CANCER-POLICY-SUPPORT@ec.europa.eu.

☒ **I hereby declare the information disclosed in this form is true and complete to the best of my knowledge.**

☒ **I agree my DoI form to be publicly available on the EC's web-hub on cancer screening and care, during the EC-LuC membership[11].**

☒ **I am informed that my personal data are stored, processed and published by the EC in accordance with Regulation (EU) 2018/1725[12].**

Name and Surname:
Martina Vrankar

Date: 27.7.2026

Signature: MARTINA VRANKAR Digitally signed by MARTINA VRANKAR Date: 2026.07.27 19:20:14 +02'00'

Place: Ljubljana, Slovenia

[10] Personal data processing including the DoI
https://ec.europa.eu/dpo-register/detail/DPR-EC-00656
[11] Note: Technical measures are in place to ensure that search engines do not index the content from the DoI form.
[12] Protection of individuals with regard to the processing of personal data
https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32018R1725